THE NEED FOR PREVENTATIVE DIAGNOSIS AND NEW BIOMARKERS (ASYMPTOMATIC) FOR ACUTE RENAL FAILURE

On October 26, 2021, at Liv Hospital Vadi Istanbul Hospital, Prof. Dr. Our Argeron NephrotesT product, which provides early detection of acute kidney injury, was introduced by Abdullah Olgun to the biochemistry specialists of Medical Park and Liv Hospital, both face-to-face and online. At the meeting, detailed information was given to the participants about the reason for the development of Argeron NephroTest, the need for the product and how to use it.

Argeron NephroTesT has also provided a solution to the increasing problem of acute kidney injury and kidney failure, which is increasing worldwide, due to the fact that symptomatic biomarkers (creatinine, urea, etc.) are not sufficient for preventive diagnosis, follow-up and diagnosis.

Argeron NephroTesT measures the stress of the kidney by measuring the increase in trehalase activity in the urine long before the decrease in GFR (Glomerular Filtration Rate) and can provide the necessary precautions to be taken by making a preventive diagnosis before a more permanent damage to the kidney occurs.

Argeron Medical Research San. ve Tic. Inc. Chairman of the board, Bülent BIDI, stated at the end of the meeting that if all academicians who want to conduct scientific research apply to them, test donations will be made.

For more detailed information about the product, you can visit the website www.nephrotest.com.